In addition to somatostatin analogues, chemotherapeutic regimes, and radiolabeled peptide receptor treatments (e.g., PRRT), tumor-targeted therapies such as tyrosine kinase inhibitor (TKI, i.e., sunitinib) and especially mammalian target of rapamycin (mTOR) inhibitors (everolimus) are well established [3,4,5,6]. Here, MTOR is linked to neoplasm.